Replies to post #35915 on Intellipharmaceutics International Inc. (IPCI)

[doogdilinger]

He doesn't care about the core shareholders...if he did he would've listened to them years ago but chose not to.

I mean how many of us took the time to participate in that shareholder survey last September after new CFO Patient came onboard...yet not 1 single thing changed.

No Press Releases, no pay cuts, no mgmt. adjustments, no changes whatsoever in how their story was portrayed to market etc etc etc

All that occurred was more of the exact same conditions that led them into the FUD factors in the 1st place.

Dr. Odidi and all of his mgmt. team and employees haven't been effected by the market erosion one iota. They all continue getting paid and when the reverse split occurs in about 3 weeks...they will continue getting paid.

I know that some believe Odidi has just as much to lose as the rest of us due to the IPCI shares he holds...but quite frankly affiliate stock only becomes relevant if/when the day ever comes that a PubCo like IPCI succeeds...and we can all see that IPCI has failed 9+ years into the dream and it's over for all the remaining round 1 believers.

And quite frankly I hold little faith that anything's gonna change in the post reverse split era...all that will occur is more dilutive offerings, an ongoing failed generics pipeline and maybe just maybe some advancement on their Oxycontin NDA candidate to the point where they refile it with the FDA and get another adcom scheduled.

But that's at least another year away...and by then another +$13M will be burned through...which means another 3 X $5M dilutive offerings will be sold b4 IPCI ever gets back in front of another adcom for their Oxycontin NDA candidate.

FocalinXR and SeroquelXR combined may generate this company $1M in revenue during this calendar year if we're lucky...and quite frankly that's woeful and pathetic results for a company that's spent 10's of millions of dollars and 9 and a half years trying to create any semblance of shareholder value!

Dr. Odidi started out strong until the FocalinXR debacle started unfolding in the spring of 2014...from that point forward IPCI's been on a painfully slow ride to hell with Dr. Odidi incapable of making any timely or proper adjustments along the way to combat the constant waves of negatives sinking the IPCI ship!

[Samsa]

Fabius, I think That is where we need to focus our attention. As doog pointed out in the post immediately prior, we all know what the history and how we got to this point. Between his management AND the games being played we are where we are. The question is where can we possibly go ?

Honestly, I do not see delisting as an issue at this point. The recent reclassification of the warrants as now shares exercise-able at the strike prices allowed Odidi to carry those shares are shareholder equity and which is why they are now counted in the float. Equity that he can just not throw away paying the high salaries. at least not until he does something to get share price to the strike prices.

So that coupled with an RS allows us to maintain compliance. so taking that off the table where do we sit or what is in the future?

It still does not ease the cash flow issue. So I see 3 options;
option 1, he inks a deal even without up front payment. signing a deal for both Regabatin and Rexista could pop the share price to the $3 range assuming he tells us the value is worth say 50 million each in future milestone payments. A 10 to 1 RS would then put us at $30 a shares with 5 million outstanding shares. He could then sell only 500k shares at get 15 million dollars! which would only amount to 10% of the company.

Option 2, he dilutes either before or even after the RS. with no news we sit at 35 cents. a RS of 10 to 1 gets us only to $3.50. He would need to then sell, 1.5 million shares or 25% of the company just to get 5 million dollars and keep the doors open another quarter.

If he takes option 2, he will lose control of the company and be forced out. Is that really a bad thing???? I could see us recovering from that just taking longer.

option 3 of course would be ink a deal with upfront monies. that would stave off further dilution for a time. are there any out there however? Possibly maybe with good HAP studies for Rexista however we dont expect those studies to be complete until September or October. so that wont help the immediate need for cash which is why I feel it will be option 1 or 2.

what do others think? I feel we do have to look for what the worse case is at this point and plan for it and right now Options 1 or 2 are what I perceive as our worst cases.